Journal
BIOCHEMICAL SOCIETY TRANSACTIONS
Volume 40, Issue -, Pages 20-25Publisher
PORTLAND PRESS LTD
DOI: 10.1042/BST20110689
Keywords
angiogenesis; anti-VEGF therapy; biomarker; neuropilin; receptor tyrosine kinase (RTK); vascular endothelial growth factor (VEGF)
Categories
Funding
- Uppsala University
- Swedish Cancer Foundation
- Swedish Science Council
- Wallenberg Foundation
- Gustaf Adolf Johansson's Foundation, at Uppsala University
Ask authors/readers for more resources
VEGFs (vascular endothelial growth factors) are master regulators of vascular development and of blood and lymphatic vessel function during health and disease in adults. This family of five mammalian ligands acts through three RTKs (receptor tyrosine kinases). In addition, co-receptors such as NRPs (neuropilins) associate with the ligand-receptor signalling complex and modulate the output. Therapeutics to block several of the VEGF signalling components as well as NRP function have been developed with the aim of halting blood vessel formation, angiogenesis, in diseases that involve tissue growth and inflammation, such as cancer. The present review outlines the current understanding of NRPs in relation to blood and lymphatic vessel biology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available